Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.38% | -20.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.97% | -2.48% | |||
| Operating Income | -10.97% | 2.48% | |||
| Income Before Tax | -4.75% | -7.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.75% | -7.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.75% | -7.63% | |||
| EBIT | -10.97% | 2.48% | |||
| EBITDA | -11.00% | 2.49% | |||
| EPS Basic | -0.60% | -7.54% | |||
| Normalized Basic EPS | -10.31% | 1.87% | |||
| EPS Diluted | -0.60% | -7.54% | |||
| Normalized Diluted EPS | -10.31% | 1.87% | |||
| Average Basic Shares Outstanding | 4.13% | 0.09% | |||
| Average Diluted Shares Outstanding | 4.13% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||